Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study-Reference-Cited by-同舟云学术

Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study

Published:2023-09-07 Issue:10 Volume:16 Page:793-801
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Sidonio Robert F.¹,Thompson Alexis A.²,Peyvandi Flora³⁴,Stasyshyn Oleksandra⁵,Yeoh Seoh Leng⁶,Sosothikul Darintr⁷⁸,Antmen Ali Bulent⁹,Maggiore Caterina¹⁰,Engl Werner¹¹,Ewenstein Bruce¹²,Tangada Srilatha¹²

Affiliation:

1. Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA, USA

2. Division of Hematology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, USA

3. Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre and Fondazione Luigi Villa, Milan, Italy

4. Department of Pathophysiology and Transplantation, Universitàdegli Studi di Milano, Milan, Italy

5. Academy of Medical Sciences of Ukraine, Lviv, Ukraine

6. Department of Pediatrics, Hospital Pulau Pinang, George Town, Malaysia

7. Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

8. Integrative and Innovative Hematology/Oncology Research Unit, Faculty of Medicine, Chulalonkorn University, Bangkok, Thailand

9. Department of Pediatric Hematology and Oncology, Acibadem Adana Hospital, Adana, Turkey

10. IQVIA, Milan, Italy

11. Pharmacometrics & Biostatistics, Baxalta Innovations GmbH, A Takeda Company, Vienna, Austria

12. Takeda Development Center Americas, Inc., Cambridge, MA, USA

Funder

Takeda Development Center Americas, Inc., Lexington, MA, USA and Baxalta Innovations GmbH, a Takeda company, Vienna, Austria

Publisher

Informa UK Limited

Subject

Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474086.2023.2247160

Reference34 articles.

1. The Hemophilias — From Royal Genes to Gene Therapy

2. Haemophilias A and B

3. WFH Guidelines for the Management of Hemophilia, 3rd edition

4. The past and future of haemophilia: diagnosis, treatments, and its complications

5. Aspects of prophylactic treatment of hemophilia